Prelude Therapeutics’ lead asset…
Prelude Therapeutics’ lead asset won’t be making it to the [...]
Having backed Superluminal…
Having backed Superluminal Medicines’ series A last year, Eli Lilly [...]
Schrödinger is abandoning its…
Schrödinger is abandoning its CDC7 inhibitor after the therapy was [...]
A patient has died from kidney…
A patient has died from kidney injury in a trial [...]
Sarepta Therapeutics is selling…
Sarepta Therapeutics is selling off Arrowhead Pharmaceuticals shares to stretch [...]
Vedanta Biosciences’ dreams of…
Vedanta Biosciences’ dreams of using live bacteria to treat inflammatory [...]
Hatteras Venture Partners has…
Hatteras Venture Partners has secured over $200 million across a [...]
More bad news has come down for…
More bad news has come down for Biohaven’s small molecule [...]
The director of the National…
The director of the National Institutes of Health has attributed the [...]
After HHS abruptly canceled about…
After HHS abruptly canceled about $500 million in funding for [...]